Subcutaneous Injection Sites: Log Your Rotation
You don't have to keep this in your head. This subcutaneous injection sites reference covers the body areas named in patient instructions and what sources say about rotation. Your prescriber or your label names the areas to use, and this page shows those areas on a body map. To log where each injection went, use the free tracker.
Body map
A reference diagram of areas. Tap an area or its button to mark it in this view. Nothing is saved or sent, and this map does not suggest where to inject. The areas your product allows are in its instructions.
No areas marked. Nothing is saved.
Math based on your entries. Check it against the print on your syringe. Not medical advice.
What 'subcutaneous' means
As of Revised 10/2025 and Revised 02/2026, labels say to inject "subcutaneously." Some name the abdomen, thigh, and upper arm for products in this class: FDA-approved GLP-1 label (opens in a new tab), FDA-approved GLP-1 label (opens in a new tab). For your notes, write the route and area exactly as your label or Instructions for Use print them.
Areas named in patient instructions
As of January 2026, the ADA says sites for insulin administration include the abdomen, thigh, buttock, and upper arm: ADA: Standards of Care in Diabetes 2026, section 9 (opens in a new tab). In your notes, copy the body area name exactly as written on your plan or label.
Reviewed March 2022, NIDDK also names the belly, thigh, buttocks, and upper arm as places used for insulin: NIDDK: Insulin, Medicines, & Other Diabetes Treatments (opens in a new tab). Terms can vary. If your paperwork uses different wording, write that wording down so your log matches it.
As of Revised 10/2025, Revised 02/2026, and Revised 01/2026 to Revised 02/2026, labels in this category name the abdomen, thigh, and upper arm: FDA-approved GLP-1 label (opens in a new tab), FDA-approved GLP-1 label (opens in a new tab), FDA-approved GLP-1 label (opens in a new tab), FDA-approved GLP-1 label (opens in a new tab). Some also say another person may use the back of the upper arm. In your notes, use the same area terms your label uses.
Why people rotate
As of January 2026, the ADA says site rotation is necessary and says people using insulin should be taught rotation: ADA: Standards of Care in Diabetes 2026, section 9 (opens in a new tab). For your notes, record the area each time. Memory gets fuzzy.
Reviewed March 2022, NIDDK says injecting in the same spot repeatedly could make the tissue harden, so people may alternate spots: NIDDK: Insulin, Medicines, & Other Diabetes Treatments (opens in a new tab). A simple log gives you a written record of what you used recently.
As of 07/28/2022, ADCES defines rotation as changing the places on the body where insulin is injected: ADCES: injection site rotation (opens in a new tab). Write the body area after each entry, so your history stays visible on one screen.
As of Revised 02/2026, one label says to rotate the injection site with each injection: FDA-approved GLP-1 label (opens in a new tab). As of Revised 10/2025, another says to use a different injection site each week when injecting in the same body region: FDA-approved GLP-1 label (opens in a new tab). If your label uses either phrase, copy it into your notes.
Keep a rotation log
A log helps when your phone is propped against a mug. Use Log this injection to mark the area you used, or open the peptide tracker or GLP-1 tracker if those fit the rest of your notes better. If it fits your routine, you can also use See your 90-day map to review recent areas.
Printable rotation log
If you want paper, keep one sheet with your dates and area names beside your printable charts. Keep the wording the same. That way, your paper notes and screen log match.
Printable site log
Free PDF with a body map and a month grid.
- Injection site log: US Letter (PDF, 145 KB), A4 (PDF, 143 KB)
Read this first. Information only, not medical advice. This site does not recommend amounts. Talk to your prescriber or pharmacist about your own situation. 18+.
Editorial review against cited sources. Last checked Oct 12, 2026.
Sources
- OZEMPIC (semaglutide) Prescribing Information (full label with Medication Guide and Instructions for Use) (opens in a new tab), U.S. Food and Drug Administration (Drugs@FDA label). Revised 10/2025.
- WEGOVY (semaglutide) Prescribing Information (full label with Medication Guide and Instructions for Use) (opens in a new tab), U.S. Food and Drug Administration (Drugs@FDA label). Revised 02/2026.
- ADA: Standards of Care in Diabetes 2026, section 9 (opens in a new tab), American Diabetes Association. January 2026.
- NIDDK: Insulin, Medicines, & Other Diabetes Treatments (opens in a new tab), National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Reviewed March 2022.
- MOUNJARO (tirzepatide) Prescribing Information (full label with Medication Guide and Instructions for Use) (opens in a new tab), U.S. Food and Drug Administration (Drugs@FDA label). Revised 01/2026.
- ZEPBOUND (tirzepatide) Prescribing Information (full label with Medication Guide and Instructions for Use) (opens in a new tab), U.S. Food and Drug Administration (Drugs@FDA label). Revised 02/2026.
- ADCES: injection site rotation (opens in a new tab), Association of Diabetes Care & Education Specialists (ADCES). 07/28/2022.